KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Other Operating Expenses: 2015-2025

Historic Other Operating Expenses for Rigel Pharmaceuticals (RIGL) over the last 7 years, with Sep 2025 value amounting to $4.8 million.

  • Rigel Pharmaceuticals' Other Operating Expenses fell 40.78% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.5 million, marking a year-over-year increase of 16.86%. This contributed to the annual value of $18.6 million for FY2024, which is 162.26% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Other Operating Expenses stood at $4.8 million for Q3 2025, which was up 5.53% from $4.5 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Other Operating Expenses registered a high of $8.0 million during Q3 2024, and its lowest value of $121,000 during Q1 2022.
  • Its 3-year average for Other Operating Expenses is $3.6 million, with a median of $3.8 million in 2023.
  • In the last 5 years, Rigel Pharmaceuticals' Other Operating Expenses soared by 1,148.60% in 2021 and then tumbled by 61.71% in 2022.
  • Over the past 5 years, Rigel Pharmaceuticals' Other Operating Expenses (Quarterly) stood at $4.0 million in 2021, then tumbled by 58.53% to $1.7 million in 2022, then spiked by 128.04% to $3.8 million in 2023, then soared by 52.74% to $5.8 million in 2024, then crashed by 40.78% to $4.8 million in 2025.
  • Its Other Operating Expenses was $4.8 million in Q3 2025, compared to $4.5 million in Q2 2025 and $4.4 million in Q1 2025.